{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:24:40Z","timestamp":1760909080915,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11060-016-2241-7","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T19:02:06Z","timestamp":1487185326000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial"],"prefix":"10.1007","volume":"131","author":[{"given":"Marc C.","family":"Chamberlain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Colman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan T.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Raizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"2241_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-007-0243-4","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK et al (2007) WHO classification of tumors of the central nervous system. Acta Neuropathol. doi: 10.1007\/s00401-007-0243-4","journal-title":"Acta Neuropathol"},{"key":"2241_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bpa.12171","volume":"24","author":"DN Louis","year":"2014","unstructured":"Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A et al (2014) International Society of Neuropathology\u2014s. Brain Pathol Zurich Switz 24:429\u2013435","journal-title":"Brain Pathol Zurich Switz"},{"key":"2241_CR3","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H et al (2015) Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499\u20132508","journal-title":"N Engl J Med"},{"key":"2241_CR4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ng.3273","volume":"47","author":"H Suzuki","year":"2015","unstructured":"Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458\u2013468","journal-title":"Nat Genet"},{"key":"2241_CR5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00401-014-1370-3","volume":"129","author":"DE Reuss","year":"2015","unstructured":"Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an \u201cintegrated\u201d diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133\u2013146","journal-title":"Acta Neuropathol"},{"issue":"26","key":"2241_CR6","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1056\/NEJMe1506813","volume":"372","author":"DW Ellison","year":"2015","unstructured":"Ellison DW (2015) Multiple molecular data sets and the classification of adult diffuse gliomas. N Engl J Med 372(26):2555\u20132557","journal-title":"N Engl J Med"},{"issue":"26","key":"2241_CR7","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"DJ Brat","year":"2015","unstructured":"Brat DJ, Verhaak RG et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372(26):2481\u20132498","journal-title":"N Engl J Med"},{"issue":"3","key":"2241_CR8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164(3):550\u2013563","journal-title":"Cell"},{"key":"2241_CR9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","volume":"31","author":"MJ Bent Van den","year":"2013","unstructured":"Van den Bent MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344\u2013350","journal-title":"J Clin Oncol"},{"key":"2241_CR10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","volume":"31","author":"G Cairncross","year":"2013","unstructured":"Cairncross G et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337\u2013343","journal-title":"J Clin Oncol"},{"key":"2241_CR11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1200\/JCO.2013.49.3726","volume":"32","author":"JG Cairncross","year":"2014","unstructured":"Cairncross JG, Wang M, Jenkins RB et al (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors Is associated with mutation of IDH. J Clin Oncol 32:783\u2013790","journal-title":"J Clin Oncol"},{"key":"2241_CR12","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","volume":"15","author":"M Weller","year":"2014","unstructured":"Weller M, van den Bent M, Hopkins K et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15:e395\u2013e403","journal-title":"Lancet Oncol"},{"key":"2241_CR13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-319-12048-5_6","volume":"163","author":"W Wick","year":"2015","unstructured":"Wick W, Wiestler B, Platten M (2015) Treatment of anaplastic glioma. Cancer Treat Res 163:89\u2013101","journal-title":"Cancer Treat Res"},{"key":"2241_CR14","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1200\/JCO.2009.23.6497","volume":"27","author":"W Wick","year":"2009","unstructured":"Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine and vincristine or temozolomide. J Clin Oncol 27:5874\u20135880","journal-title":"J Clin Oncol"},{"key":"2241_CR15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","volume":"28","author":"JR Perry","year":"2010","unstructured":"Perry JR, Belanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051\u20132057","journal-title":"J Clin Oncol"},{"key":"2241_CR16","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","volume":"17","author":"WK Yung","year":"1999","unstructured":"Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse, temodal brain tumor group. J Clin Oncol 17:2762\u20132771","journal-title":"J Clin Oncol"},{"key":"2241_CR17","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1200\/JCO.2003.12.097","volume":"1","author":"KA Jaeckle","year":"2003","unstructured":"Jaeckle KA, Hess KR, Yung WK et al (2003) Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American brain tumor consortium study. J Clin Oncol 1:2305\u20132311","journal-title":"J Clin Oncol"},{"issue":"9","key":"2241_CR18","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.6004\/jnccn.2013.0132","volume":"11","author":"LB Nabors","year":"2013","unstructured":"Nabors LB, Ammirati M, Bierman PJ et al (2013) Central nervous system cancers. J Natl Compr Cancer Netw 11(9), 1114\u20131151","journal-title":"J Natl Compr Cancer Netw"},{"key":"2241_CR19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","volume":"345","author":"H Brem","year":"1995","unstructured":"Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008\u20131012","journal-title":"Lancet"},{"key":"2241_CR20","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1200\/JCO.2005.03.4157","volume":"23","author":"SE Combs","year":"2005","unstructured":"Combs SE, Thilmann C, Edler L et al (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863\u20138869","journal-title":"J Clin Oncol"},{"key":"2241_CR21","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","volume":"28","author":"SE Fogh","year":"2010","unstructured":"Fogh SE, Andrews DW, Glass J et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048\u20133053","journal-title":"J Clin Oncol"},{"key":"2241_CR22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-008-9722-2","volume":"91","author":"MC Chamberlain","year":"2009","unstructured":"Chamberlain MC, Johnston S (2009) Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neuro-Oncol 91:359\u2013367","journal-title":"J Neuro-Oncol"},{"key":"2241_CR23","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/neuonc\/nor091","volume":"13","author":"TN Kreisl","year":"2011","unstructured":"Kreisl TN, Zhang W, Odia Y et al (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-Oncology 13:1143\u20131150","journal-title":"Neuro-Oncology"},{"key":"2241_CR24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-014-1714-9","volume":"122","author":"MC Chamberlain","year":"2015","unstructured":"Chamberlain MC (2015) Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. J Neuro-Oncol 122:329\u2013338","journal-title":"J Neuro-Oncol"},{"key":"2241_CR25","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","volume":"27","author":"BD Cheson","year":"2009","unstructured":"Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27:1492\u20131501","journal-title":"J Clin Oncol"},{"issue":"6","key":"2241_CR26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd2596","volume":"7","author":"MJ Keating","year":"2008","unstructured":"Keating MJ, Bach C, Yasothan U, Kirkpatrick P (2008) Bendamusttine. Nat Rev Drug Discov 7(6):473\u2013474","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2241_CR27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J et al (2008) Bendamustine (treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14(1):309\u2013317","journal-title":"Clin Cancer Res"},{"unstructured":"Bendamustine hydrochloride (CEP-18083) Investigators brochure, Cephalon Edition 2. Release date: March 4, 2010","key":"2241_CR28"},{"issue":"3","key":"2241_CR29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11060-011-0612-7","volume":"105","author":"MC Chamberlain","year":"2011","unstructured":"Chamberlain MC, Johnston SA (2011) Salvage chemotherapy with single agent bendamustine for recurrent glioblastoma. J Neuro-Oncol 105(3):523\u2013530","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"2241_CR30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-014-1411-8","volume":"18","author":"MC Chamberlain","year":"2014","unstructured":"Chamberlain MC (2014) Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. J Neuro-Oncol 18(1):155\u2013162","journal-title":"J Neuro-Oncol"},{"key":"2241_CR31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR MacDonald","year":"1990","unstructured":"MacDonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280","journal-title":"J Clin Oncol"},{"key":"2241_CR32","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","volume":"17","author":"ET Wong","year":"1999","unstructured":"Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572\u20132578","journal-title":"J Clin Oncol"},{"issue":"12","key":"2241_CR33","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2003.08.045","volume":"21","author":"HA Fine","year":"2003","unstructured":"Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21(12):2299\u20132304","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-016-2241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-016-2241-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-016-2241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T14:49:48Z","timestamp":1568818188000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-016-2241-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2241"],"URL":"https:\/\/doi.org\/10.1007\/s11060-016-2241-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}